{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:48:39Z","timestamp":1792586919059,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007656","name":"Loyola University Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Theoretical Biology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jtbi.2026.112595","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:06:44Z","timestamp":1789427204000},"page":"112595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions"],"prefix":"10.1016","volume":"636","author":[{"given":"Adquate","family":"Mhlanga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Shekhtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-3379","authenticated-orcid":false,"given":"Ashish","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-5575","authenticated-orcid":false,"given":"Maria Paola","family":"Anolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Colonia","family":"Uceda Renteria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Sambarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perbellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5252-4744","authenticated-orcid":false,"given":"Floriana","family":"Facchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapaola","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Cotler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harel","family":"Dahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtbi.2026.112595_b0005","unstructured":"AHRQ, 2022. Agency for Healthcare Research and Quality. Precision Standards Guidelines for Reporting MEPS-HC Descriptive Statistics. https:\/\/meps.ahrq.gov\/survey_comp\/precision_guidelines.shtml."},{"key":"10.1016\/j.jtbi.2026.112595_b0010","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/psp4.13003","article-title":"Model-based prediction of progression-free survival for combination therapies in oncology","volume":"12","author":"Baaz","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.jtbi.2026.112595_b0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/psp4.12404","article-title":"NONMEM tutorial Part I: description of commands and options, with simple examples of population analysis","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"key":"10.1016\/j.jtbi.2026.112595_b0020","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/psp4.12422","article-title":"NONMEM tutorial Part II: estimation methods and advanced examples","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jtbi.2026.112595_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10928-010-9175-z","article-title":"The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects","volume":"38","author":"Chan","year":"2011","journal-title":"J. Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.jtbi.2026.112595_b0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.22586","article-title":"Modeling complex decay profiles of hepatitis B virus during antiviral therapy","volume":"49","author":"Dahari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jtbi.2026.112595_b0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/liv.12692","article-title":"Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics","volume":"35","author":"Dahari","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.jtbi.2026.112595_b0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejpb.2023.05.007","article-title":"Towards a population pharmacokinetic\/pharmacodynamic model of anti-VEGF therapy in patients with age-related macular degeneration","volume":"188","author":"Del Amo","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jtbi.2026.112595_b0045","series-title":"4th International Delta Cure Meeting (delta Cure 2025)","article-title":"Virological and biochemical responses to initial and retreatment bulevirtide monotherapy in chronic hepatitis D","author":"Deterding","year":"2025"},{"key":"10.1016\/j.jtbi.2026.112595_b0050","article-title":"Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy","volume":"7","author":"El Messaoudi","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jtbi.2026.112595_b0055","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cpt.2798","article-title":"A semi-mechanistic model to characterize the long-term dynamics of hepatitis B virus markers during treatment with lamivudine and pegylated interferon","volume":"113","author":"El Messaoudi","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jtbi.2026.112595_b0060","article-title":"Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide","volume":"6","author":"El Messaoudi","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jtbi.2026.112595_b0065","doi-asserted-by":"crossref","first-page":"17820","DOI":"10.1038\/s41598-020-74568-x","article-title":"Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a pilot study","volume":"10","author":"Etzion","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jtbi.2026.112595_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11040235","article-title":"Modeling between-subject variability in subcutaneous absorption of a fast-acting insulin analogue by a nonlinear mixed effects approach","volume":"11","author":"Faggionato","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.jtbi.2026.112595_b0075","unstructured":"FDA, 2026. FDA approves first treatment for chronic hepatitis delta virus (HDV) infection. U.S. Food and Drug Administration, Silver Spring, MD (FDA headquarters), Press release, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-chronic-hepatitis-delta-virus-hdv-infection."},{"key":"10.1016\/j.jtbi.2026.112595_b0080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-020-80594-6","article-title":"Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection","volume":"11","author":"Kadelka","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jtbi.2026.112595_b0085","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jtbi.2026.112595_b0090","unstructured":"Lixoft, 2024. Monolix Suite 2024R1: Release Notes., Vol. 2024. Lixoft."},{"key":"10.1016\/j.jtbi.2026.112595_bib131","doi-asserted-by":"crossref","first-page":"106489","DOI":"10.1016\/j.antiviral.2026.106489","article-title":"Mathematical modeling of HDV RNA, HBsAg, and ALT kinetics in patients with compensated cirrhosis: Insights from 96 weeks of bulevirtide monotherapy","volume":"253","author":"Mhlanga","year":"2026","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jtbi.2026.112595_b0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jtbi.2026.112595_b0100","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2021.12.030","article-title":"Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation","volume":"76","author":"Shekhtman","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtbi.2026.112595_b0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11894-023-00901-9","article-title":"Hepatitis D virus and HBsAg dynamics in the era of new antiviral treatments","volume":"25","author":"Shekhtman","year":"2023","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.jtbi.2026.112595_b0110","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1038\/s41598-020-64122-0","article-title":"Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg","volume":"10","author":"Shekhtman","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jtbi.2026.112595_b0115","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/psp4.12500","article-title":"Efficient pharmacokinetic modeling workflow with the monolixsuite: a case study of remifentanil","volume":"9","author":"Traynard","year":"2020","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.jtbi.2026.112595_b0120","first-page":"S309","article-title":"Bulevirtide monotherapy in patients with compensated cirrhosis and CSPH: a 96-week interim kinetic analysis of real-life setting","volume":"80","author":"Wasserman","year":"2024","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1016\/j.jtbi.2026.112595_b0125","first-page":"A117","article-title":"Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up","volume":"74","author":"Wedemeyer","year":"2025","journal-title":"Gut"},{"issue":"Suppl. 1","key":"10.1016\/j.jtbi.2026.112595_b0130","first-page":"S2245","article-title":"Persistent low viremic relapse vs high viremic relapse after the end of treatment with bulevirtide with or without pegylated interferon in patients with chronic hepatitis delta virus","volume":"82","author":"Zoulim","year":"2025","journal-title":"Hepatology"}],"container-title":["Journal of Theoretical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519326002195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519326002195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:30:51Z","timestamp":1792585851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022519326002195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":27,"alternative-id":["S0022519326002195"],"URL":"https:\/\/doi.org\/10.1016\/j.jtbi.2026.112595","relation":{},"ISSN":["0022-5193"],"issn-type":[{"value":"0022-5193","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions","name":"articletitle","label":"Article Title"},{"value":"Journal of Theoretical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtbi.2026.112595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112595"}}